Table 1.
Demographics of study participants
| Cases (n = 482) | Controls (n = 482) | p-value | |
|---|---|---|---|
| Age at enrollment (median, IQR) | 64 (56–73) | 64 (57–74) | 0.40 |
| Age group (n, %)∗ | NA | ||
| <55 | 100 (20.7) | 100 (20.7) | . |
| 55–65 | 152 (31.5) | 152 (31.5) | . |
| >65 | 230 (47.7) | 230 (47.7) | . |
| Sex (n, %)∗ | NA | ||
| Male | 197 (40.9) | 197 (40.9) | . |
| Female | 285 (59.1) | 285 (59.1) | . |
| Vaccine (n, %)∗ | NA | ||
| Pfizer-BioNTech | 240 (49.8) | 240 (49.8) | . |
| Moderna | 207 (42.9) | 207 (42.9) | . |
| AstraZeneca/mRNA | 35 (7.3) | 35 (7.3) | . |
| Study visit (n, %)∗ | NA | ||
| 28 days after 3rd dose | 470 (97.5) | 470 (97.5) | . |
| Up to 170 days after 3rd dose | 12 (2.5) | 12 (2.5) | . |
| Charlson Comorbidity Index (n, %) | <0.0001 | ||
| 0 | 399 (82.8) | 346 (71.8) | . |
| 1–2 | 78 (16.2) | 115 (23.9) | . |
| >2 | 5 (1.0) | 21 (4.4) | . |
| Days from 3rd vaccine to study visit (median, IQR) | 29 (27–33) | 29 (27–32) | 0.045 |
| Days from study visit to PCR test (median, IQR) | 36 (25–50) | 29 (18–42) | <0.0001 |
The demographic characteristics of the cases (n = 482) and controls (n = 482). The categorical variables are described as number of participants (n) and the percentage (%), while the continuous variables are described as the median and the interquartile range (IQR). The matched variables are indicated with an asterisk (∗).